 | • レポートコード：MRC2103C087 • 出版社/出版日：Mordor Intelligence / 2021年2月25日 • レポート形態：英文、PDF、121ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料では、世界の麻酔薬市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、医薬品種類別（全身麻酔薬、局所麻酔薬）分析、投与経路別（吸入、注射、その他）分析、用途別（一般手術、形成外科手術、美容整形手術、歯科手術、その他）分析、地域別分析、競争状況、市場機会/将来の見通しなどを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の麻酔薬市場規模：医薬品種類別（全身麻酔薬、局所麻酔薬） ・世界の麻酔薬市場規模：投与経路別（吸入、注射、その他） ・世界の麻酔薬市場規模：用途別（一般手術、形成外科手術、美容整形手術、歯科手術、その他） ・世界の麻酔薬市場規模：地域別 ・競争状況 ・市場機会/将来の見通し |
The Anesthesia Drugs Market is expected to value USD 6,071 million in 2020 and is expected to reach USD 7,523 million in 2026, registering a CAGR of nearly 3.64% during the forecast period.
The demand for anesthetic drugs observed a slight decline in 2020 due to the emergence of the pandemic situation, leading to delayed or canceled surgeries. According to the study published in the British Journal of Surgery, in May 2020, based on a 12-week period of peak disruption to hospital services due to COVID-19, around 28.4 million elective surgeries worldwide was estimated to be canceled or postponed in 2020. However, as the activities are resuming, all the elective surgeries that were held up are also being performed now, thereby rising the consumption of anesthetic drugs.
Furthermore, the primary factors propelling the growth of this market are the rising number of surgeries and new anesthetic drug approval. According to the International Society of Aesthetic Plastic Surgery report, in 2019, the volume of plastic surgeries performed globally observed an increase of about 7.4% in comparison to the last year (2018). This indicates the rising number of surgeries, which ultimately results in the rising demand for anesthesia drugs.
Also, according to the United Nations Department of Economic and Social Affairs, by 2050, one in four persons living in Europe and Northern America could be aged 65 or over. An increase in the elderly population has led to a steep increase in the number of chronic diseases in the elderly like cardiovascular, neurological further leading to the rising demand for anesthesia drugs.
Moreover, in June 2019, Fresenius Kabi announced the immediate availability of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a medication for sedation of non-intubated patients before and/or during surgical and other procedures. Hence, this is expected to propel the growth of the anesthesia drugs market.
Key Market Trends
Propofol Sub-segment is Expected to Show the Fastest Growth in the General Anesthesia Drugs Segment
Propofol is one of the most commonly used general anesthetic drugs in surgeries and as a sedative for critical care (including those with COVID-19) in the ICU. It is used for the initiation and maintenance of procedural sedation, general anesthesia, etc. In June 2020, the United States Food & Drug Administration approved the use of Fresenius Propoven 2% emulsion for maintaining sedation for COVID-19 patients (16 years and above) requiring mechanical ventilation.
Propofol is also used for the and induction maintenance of anesthesia and the management of refractory status epilepticus. The drug has been used for a long time, for various types of surgical procedures that require anesthesia. The companies that manufacture the propofol injections are Neon Laboratories Limited, Bharat Serums and Vaccines Limited, and Fresenius Kabi.
Furthermore, according to the as per data provided by Organization Economic Co-operation and Development, in Germany, the total number of coronary artery bypass grafting procedures performed were 45,307 in 2018. Hence with the increasing incidences of emergency surgeries, extensive usage of the drug, short-acting characteristic and a growing number of surgical procedures worldwide, are the major factors propelling the growth of the market.
North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period
North America currently dominates the anesthesia drugs market and is expected to continue its stronghold for a few more years. The United States anesthesia is the largest regional market in the world. With the emergence of COVId-19, the is the United States faced heavy shortages of vital anesthetic drugs, particularly, dexmedetomidine, midazolam, propofol, and neuromuscular blocking agents. As a result, many of the companies are ramping up their production of anesthesia drugs. For instance, in May 2020, Hikma Pharmaceutical introduced a new product “Propofol Injectable Emulsion” in the United States.
Furthermore, this market is driven by factors, such as the increasing number of surgeries, rising aging population with increasing chronic conditions, and advancements in anesthesia technologies. As per the statistics provided by the American Society of Plastic Surgeons (ASPS) 2019, there are almost 1.8 million cosmetic surgical procedures and 16.3 million cosmetic minimally-invasive procedures being performed in the United States in 2019. The demand for various anesthetics goes hand-in-handwith surgical procedures that are being performed. The application of anesthetic drugs in general surgeries are expected to continue to contribute significantly to the growth of the market.
Moreover, new anesthesia drugs are being developed in the country which is expected to propel the market growth. For instance, in June 2020, Medova and the New York School of Regional Anesthesia (NYSORA) went under partnership for the introduction of SAFIRA (SAFer Injection for Regional Anesthesia) in the United States. Also, in January 2020, Food & Drug Administration approved new drug application for cocaine hydrochloride (HCI; NUMBRINO) nasal solution 4% (40 mg/mL) as an anesthetic use, manufactured by Lannett Company in the United States.
Competitive Landscape
The anesthesia drugs market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with rising drug approvals, mid-size to smaller companies are increasing their market presence by introducing new ingredients with fewer prices. In August 2020, the PAION introduced ANEREM, general anesthesia in Japan. Also, in April 2020, Blue-Zone Technologies Ltd. received approval from Health Canada for desflurane, USP, an anesthetic drug used for general anesthesia. Companies, like Baxter, Abbott Laboratories, AstraZeneca, Roche Holding AG, and B. Braun Melsungen AG, hold substantial market shares in the anesthesia drugs market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Surgeries
4.2.2 New Approvals of Anesthetic Drugs
4.2.3 Reduction in the Cost of Newly Invented Drugs
4.3 Market Restraints
4.3.1 Side Effects of General Anesthetics
4.3.2 Lack of Skilled-Anesthetics
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 General Anesthesia Drugs
5.1.1.1 Propofol
5.1.1.2 Sevoflurane
5.1.1.3 Desflurane
5.1.1.4 Dexmedetomidine
5.1.1.5 Remifentanil
5.1.1.6 Midazolam
5.1.1.7 Other General Anesthesia Drugs
5.1.2 Local Anesthesia Drugs
5.1.2.1 Bupivacaine
5.1.2.2 Ropivacaine
5.1.2.3 Lidocaine
5.1.2.4 Chloroprocaine
5.1.2.5 Prilocaine
5.1.2.6 Benzocaine
5.1.2.7 Other Local Anesthesia Drugs
5.2 By Route of Administration
5.2.1 Inhalation
5.2.2 Injection
5.2.3 Other Routes of Administration
5.3 By Application
5.3.1 General Surgery
5.3.2 Plastic Surgery
5.3.3 Cosmetic Surgery
5.3.4 Dental Surgery
5.3.5 Other Applications
5.4 Geography
5.4.1 North America
5.4.1.1 United States (By Drug Type, By Route of Administration, and By Application)
5.4.1.2 Canada (By Drug Type, By Route of Administration, and By Application)
5.4.1.3 Mexico (By Drug Type, By Route of Administration, and By Application)
5.4.2 Europe
5.4.2.1 Germany (By Drug Type, By Route of Administration, and By Application)
5.4.2.2 United Kingdom (By Drug Type, By Route of Administration, and By Application)
5.4.2.3 France (By Drug Type, By Route of Administration, and By Application)
5.4.2.4 Italy (By Drug Type, By Route of Administration, and By Application)
5.4.2.5 Spain (By Drug Type, By Route of Administration, and By Application)
5.4.2.6 Rest of Europe (By Drug Type, By Route of Administration, and By Application)
5.4.3 Asia-Pacific
5.4.3.1 China (By Drug Type, By Route of Administration, and By Application)
5.4.3.2 Japan (By Drug Type, By Route of Administration, and By Application)
5.4.3.3 India (By Drug Type, By Route of Administration, and By Application)
5.4.3.4 Australia (By Drug Type, By Route of Administration, and By Application)
5.4.3.5 South Korea (By Drug Type, By Route of Administration, and By Application)
5.4.3.6 Rest of Asia-Pacific (By Drug Type, By Route of Administration, and By Application)
5.4.4 Middle East and Africa
5.4.4.1 GCC (By Drug Type, By Route of Administration, and By Application)
5.4.4.2 South Africa (By Drug Type, By Route of Administration, and By Application)
5.4.4.3 Rest of Middle East and Africa (By Drug Type, By Route of Administration, and By Application)
5.4.5 South America
5.4.5.1 Brazil (By Drug Type, By Route of Administration, and By Application)
5.4.5.2 Argentina (By Drug Type, By Route of Administration, and By Application)
5.4.5.3 Rest of South America (By Drug Type, By Route of Administration, and By Application)
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Apsen Pharmacare Holdings Limited
6.1.3 Baxter International Inc.
6.1.4 B. Braun Melsungen AG
6.1.5 Fresenius SE & Co. KGaA
6.1.6 Hikma Pharmaceuticals PLC
6.1.7 Mylan NV
6.1.8 Pfizer Inc.
6.1.9 Piramal Enterprise LTD
6.1.10 Teva Pharmaceutical Industries Limited
6.1.11 BioQ Pharma
7 MARKET OPPORTUNITIES AND FUTURE TRENDS